FIELD: pharmaceutics.
SUBSTANCE: invention relates to compositions for oral administration for the treatment and/or prevention of conditions related to inadequate mitochondrial activity, containing medium-chain triglyceride and urolitin A. This invention also relates to a method for enhancing muscle function, improving endurance or improving, maintaining or reducing the loss of muscle function, including the administration of an effective number of compositions to the subject.
EFFECT: obtaining a composition for the treatment and/or prevention of conditions related to inadequate mitochondrial activity.
16 cl, 3 dwg, 8 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING NICOTINE AMIDRIBOSIDE AND UROLITIN | 2016 |
|
RU2751638C2 |
| ANTAGONISTS NEUROKININ-1 COMPOSITIONS FOR INTRAVENOUS INTRODUCTION | 2010 |
|
RU2642234C2 |
| LOW-DOSE PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN FOR ORAL ADMINISTRATION | 2015 |
|
RU2707753C2 |
| COMPOSITIONS AND METHODS FOR IMPROVING OR MAINTAINING MUSCLE PERFORMANCE | 2011 |
|
RU2606763C2 |
| ORAL CELECOXIB COMPOSITION FOR PAIN TREATMENT | 2017 |
|
RU2745196C2 |
| COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | 2011 |
|
RU2745439C2 |
| INJECTABLE ISOXAZOLINE PHARMACEUTICAL COMPOSITIONS AND THEIR USE | 2018 |
|
RU2799591C2 |
| COMBINATION OF COMPONENTS FOR PREVENTION AND TREATMENT OF INDISPOSITION | 2011 |
|
RU2646830C2 |
| ABT-263 CAPSULE | 2010 |
|
RU2550956C2 |
| EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION | 2019 |
|
RU2810789C2 |
